FIELD: food industry.
SUBSTANCE: invention relates to nutritional compositions for use in order to prevent, reduce the risk or mitigate a suboptimal trajectory of de novo myelination in a subject fed with a mixture. The use of a synthetic nutritional composition containing iron is proposed to prevent, reduce the risk or mitigate a suboptimal trajectory of de novo myelination in a human infant or a baby fed with a mixture, where the trajectory of de novo myelination is maintained or optimized in one or several of following brain regions: cerebellum, visual cortex, motor and somatosensory cortex, corpus callosum, frontal lobe. At the same time, a human infant is an infant under the age of 12 months, and a child is a person aged from 1 to 18 years. The trajectory of de novo myelination is suboptimal, when the distance between any equivalent and/or identical measurement points of an infant trajectory and a trajectory achieved in infants who are exclusively breastfed during their first (3) months of life exceeds 50%. The synthetic nutritional composition contains iron – at least 5 mg/100 g, and choline, and/or folic acid – at least 100 mcg/kg, and/or vitamin B12 – at least 5 mcg/100 g, and/or a fatty acid compound representing docosahexaenoic acid – at least from 60 to 350 mg/100 g, and/or arachidonic acid – at least from 60 to 350 mg/100 g, and/or sphingomyelin – at least 300 mg/kg, where the whole weight relates to the dry weight of the composition. The composition is a composition selected from a group consisting of: infant formula, milk for children from 1 to 3 years old, a composition for infants intended for addition or dilution with human breast milk, and a food product intended for consumption by an infant and/or a child either separately or in combination with human breast milk.
EFFECT: invention makes it possible to optimize the amount/degree of myelination in the subject.
11 cl, 65 dwg, 15 tbl, 6 ex
